Recruiting studies: Ganglioneuroblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 · 162 location(s) · Children's Oncology Group · NCT03126916 Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06071897 SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumour
NA · 38 location(s) · Institut Curie · NCT05192980 Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07375563 Phase II Study of Proton Radiation Therapy for Neuroblastoma
NA · 1 location(s) · Massachusetts General Hospital · NCT02112617 Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07502287 International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
Phase N/A · 1 location(s) · Debra Weese-Mayer · NCT03088020 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed
Phase 3 · 178 location(s) · National Cancer Institute (NCI) · NCT06172296 Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Phase N/A · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06296732

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.